Introduction
Monobenzyl ether of hydroquinone (MBEH) is currently in use as a Food and Drug Administration approved agent to induce depigmentation in patients with vitiligo [1] . Depigmenting qualities of the compound were first described following attempts to identify a cause for skin depigmentation in an occupational setting. This led to the description of 'occupational vitiligo' as a separate category of patients undergoing gradual depigmentation [2, 3] . Several phenolic compounds have been described, which affect depigmentation either temporarily (such as hydroquinone) or in a permanent manner, including MBEH [1] . As treatments for vitiligo are largely ineffective, and patients with advanced depigmentation of their skin sometimes prefer an even skin tone, MBEH is included as an active ingredient in monobenzone cream, used to depigment the remainder of the skin over the course of several weeks to months [4] .
The working mechanism of MBEH and other depigmenting agents is less well understood. Permanent depigmentation of the skin observed in most patients does suggest that the drug is capable of selectively eliminating melanocytes from the epidermis. Recent data showing selective cytotoxicity of MBEH toward melanocytes, and not keratinocytes, do support this viewpoint [5] . The selective action of MBEH on melanocytes has been explained by structural homology to tyrosine, the natural substrate for melanogenesis. When combined with the rate-limiting enzyme for melanogenesis, tyrosinase, MBEH is converted into a highly reactive quinone suggested to react with surrounding enzymatic compounds within the confines of the melanosomal organelle [6] . As expression of melanosomal enzymes is restricted to cells of the melanocyte lineage, the above sequence of events can explain a selective cytotoxic effect of MBEH on melanocytes. It should be considered that different phenolic compounds can follow markedly different depigmentation strategies. In this respect, although MBEH is thought to bind to tyrosinase, 4-tertiary butyl phenol (4-TBP) seems to interact with tyrosinase related protein-1 instead [7, 8] .
Quinones binding to melanosomal compounds occur in a process described as haptenization in which the hosting compound undergoes slight structural alterations [7] .
Melanosomal enzyme modification is significant as tyrosinase related protein-2 (TRP-2), melanoma antigen recognized by T cells-1 (MART-1), gp100, and tyrosinase itself are immunogenic molecules, and minor changes in the amino acid composition or even haptenization have been shown to alter their recognition by T cells reactive with the native peptide [9] . Under increased affinity for the modified peptide, immune tolerance can be broken and improved reactivity will likely ensue. This process is significant for an understanding of the depigmentation process in vitiligo.
On studying the effects of MBEH exposure on melanocyte viability, it was found that sensitivity to MBEH exposure is not directly correlated with the expression of a single melanosomal compound molecule. Rather, there was an inverse relationship noted for sensitivity to MBEH and expression of melanin within the cell. More intensely pigmented cells are thus increasingly resistant to the compound [5] . This can have implications for the treatment of ethnic skin with MBEH.
Besides an understanding of the direct effects of bleaching phenols on pigmented cells, any consequences for cell viability will indirectly affect immune responses to follow. In this regard, the markedly different effects of MBEH and 4-TBP on melanocytes manifest themselves in the induction of necrosis and apoptosis, respectively, in exposed cells [5] . Both death pathways are thought to have markedly different consequences on dendritic cell activation and it is thus likely that 4-TBP and MBEH exposures have markedly different kinetics of depigmentation in an in-vivo setting.
The mechanism of action of bleaching phenols becomes particularly important when considering the specificity for cells of the melanocytic lineage. Besides normal epidermal and ocular melanocytes, cells potentially sensitive to the effects of MBEH and 4-TBP can thus include melanoma cells. Systemic toxicity, however, limits the application of bleaching phenols in a therapeutic setting. The toxicity of both MBEH and 4-TBP toward fibroblasts, for example, is significant [5, 8] . Nevertheless, to make use of the unique qualities of bleaching phenols toward the treatment of melanoma, two supportive factors are considered here. First, eliminating melanocytes from the skin will prevent precursor cells from converting to melanoma cells by malignant transformation; thus this process may be effective as a chemical alternative to elective surgery for patients with familial melanoma, or to prevent recurrences in patients after surgical removal of a primary tumor. Second, cell death from a portion of melanocytes in the skin may elicit an immune response that carries over to an effective antitumor response by the recognition of antigens shared between melanocytes and melanoma cells [10] [11] [12] . Familial melanoma is a condition affecting approximately 10% of melanoma cases, or an estimated 6000 newly diagnosed patients per year in the United States alone [13] . If induction of vitiligo can spare patients from agonizing returning visits to the dermatologist to check for newly arising dysplastic nevi, treatment with bleaching phenols may be a more effective and permanent way to address familial disease. To study the potential of prophylactic treatment using bleaching phenols for familial melanoma, it is necessary to first identify the in-vivo effects of the agents under study in an in-vivo setting, in particular, to address anticipated involvement of an immune response. Here, the effects of bleaching agents 4-TBP and MBEH were studied initially in normal human skin, to quantify Langerhans cell emigration in response to either agent. Organotypic cultures of human skin are ideal for these studies as emigration can be studied without new influx of immune cells [14] . As Langerhans cells migrate upon antigen specific stimulation, the same approach has been followed to distinguish allergenic compounds from skin irritants [15, 16] . This same factor limits the use of skin cultures to assess T cell influx, and these studies were executed in mouse models instead. To this end, bleaching agents were applied to the skin of wild-type mice as well as a transgenic model designed to express melanocytes in the epidermal compartment of the skin. In the k14-SCF mouse, stem cell factor is expressed under the k14 promoter within keratinocytes to support melanocyte maintenance within the skin environment, which is important to follow topical application of the bleaching agents [17] . Depigmentation was quantified in both models and T cell influx, immigration of macrophages and cytokine expressions were measured in the skin. To understand whether melanoma cells are directly sensitive to bleaching agents when exposed in a topical setting, the cytotoxicity of 4-TBP and MBEH toward melanoma cells and melanocytes was compared in vitro before returning to mice to perform a B16 tumor challenge. In this experiment, mice were pretreated with MBEH and subsequently challenged with tumor cells, thus relying solely on immune effects to contain the tumor. Finally, the cytokine environment in the remaining tumor tissue and infiltration by CD8 + T cells were quantified. Taken together, these data shed important light on the prophylactic potential of bleaching agents for the treatment of familial melanoma.
Materials and methods

Mouse models
Two strains of mice, C57BL/6J (Jackson Labs, Bar Harbor, Maine, USA) and k14-SCF transgenic mice [17] were used in the depigmentation experiments. In the k14-SCF mice, mouse stem cell factor is expressed under the k14 promoter that maintains melanocytes within the epidermis, thus rendering the skin of k14-SCF mice as a close mimic of human skin. Group sizes were five per group for C57BL/6J mice and four per group for k14-SCF mice otherwise stated. All experiments were approved by Loyola University Medical Center's Institutional Animal Care and Use Committee. Mice were prepared for depigmentation treatment by biweekly ventral hair removal with Nair (Church and Dwight Co., Princeton, New Jersey, USA). C57BL/6 mice were topically treated with 100 ml of 1.5 mol/l 4-TBP or MBEH applied to a 3 cm 2 area of Naired skin on alternate days for 6 weeks. The k14-SCF mice were similarly treated with 100 ml of 1 mol/l concentration of 4-TBP or MBEH for 14 weeks. Mice were anesthetized during hair removal and bleaching phenol treatments using an isofluorane gas chamber (Euthanex Corp, Plamer, Pennsylvania).
Organotypic culture of treated human skin
Organotypic culture was performed as described earlier [14] . In brief, 4 mm biopsies were punched from otherwise discarded foreskin tissue obtained after routine circumcision. Explants were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% inactivated normal human serum at the air-liquid interphase with epidermis facing up in 12 well transwell plates with a pore size of 0.4 mmol/l (Corning, Teterboro, New Jersey, USA). After topical treatment with 5 ml of 250 mmol/l of 4-TBP or MBEH daily for 3 days, explants were embedded in an optimal cutting temperature compound (OCT) (Sakura Finetek USA, Torrance, California, USA), snap frozen, and maintained at -801C for future sectioning. All studies carried out with human tissue were in adherence with the Declaration of Helsinki Principles and were approved by the institutional review board of the institution where circumcisions were performed.
Cell culture
Mouse melanocyte cultures were initiated from untreated k14-SCF mice skin samples. After euthanasia of the mice, the skin samples were homogenized overnight in an enzymatic cocktail (0.05 mg/ml thermolysin, 1 mg/ml collagenase, 0.1 mg/ml trypsin, 0.01 mg/ml DNase) prepared in DMEM (Mediatech Inc., Manassas, Virginia, USA). Cells were cultured in Ham's F-12 medium (Mediatech) with 10% heat-inactivated fetal bovine serum (Gemini Bio-Products, West Sacramento, California, USA), 2 mmol/l glutamine (Mediatech), 100 IU/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml amphotericin (Mediatech), 0.1 mmol/l isobutylmethylxanthine (Sigma), 10 ng/ml 12-O-tetradecanoyl phorbol-13-acetate (Sigma), and 0.03% bovine pituitary extract (Invitrogen, Carlsbad, California, USA).
B16F10 mouse melanoma cells were maintained in DMEM (Mediatech) with 10% heat-inactivated fetal bovine serum (Gemini Bio-Products), 100 IU/ml penicillin, 100 mg/ml streptomycin, and 100 mg/ml amphotericin (Mediatech).
Evaluating depigmentation
Depigmentation was evaluated by flat bed scanning of the ventral side of the mice under anesthesia, and subsequent image analysis using Adobe Photoshop software (Adobe Systems Inc., San Jose, California, USA) as described earlier [18] . Depigmentation experiments were repeated three times and representative experiment was shown. In brief, depigmentation was evaluated by quantifying mean luminosity of inverted images for the treated area and by comparing the data with untreated mice. Statistical analysis of data was carried out by comparing relevant groups by Student's t-test using Excel software (Microsoft, Seattle, Washington, USA).
Immunohistology
Biopsies of treated mouse skin, treated human skin explants, or mouse tumor tissue were embedded in optimal cutting temperature compound (Sakura Finetek USA) and snap frozen on dry ice. Eight micrometer cryostat sections were fixed in cold acetone and stored at -201C until use.
Human explant sections were stained with antibody CD207 to Langerin (mouse monoclonal: Immunotech, Marselle, France). Vehicle application was used as a negative control. Migrastion of Langerhans cells was evaluated in three human skin biopsies per group.
Mouse skin sections were stained with biotinylated hamster antibody 145-2C11 to CD3e antibody (Pharmingen, San Diego, California, USA), or goat T-16 antibody to CD68 (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA). Peroxidase-labeled antimouse or antigoat antisera or peroxidase-labeled streptavidin (Southern Biotechnologies, Birmingham, Alabama, USA) was used in the second step and color was developed using aminoethyl carbazole as a substrate (Sigma) as described earlier [19] . Quantifications were performed in two serial sections from tissues of four mice/group.
Tissues from three remaining tumors/group were engaged in the evaluation of infiltrating CD8 + T cells. Tumor sections were stained with biotinylated 53-6.7 rat antibody to CD8a (Biolegend, San Diego, California, USA). Antirat Alexa Flour 568 (Invitrogen) was used as a secondary antibody. Images were captured by an Olympus BX41 bright field microscope (Olympus, Center Valley, Pennsylvania, USA).
Stained cells were counted within the epidermis for CD3 + T and Langerin + cells or to a depth of twice or four times of the epidermal thickness in the dermal regions for quantifying Langerin + and CD68 + cells, respectively; tissue length or area was calculated using Adobe Photoshop CS4 Software (Adobe Systems).
Cytotoxicity assay
Cell viability was measured by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays (Bioassay system, Hayward, California, USA) according to the manufacturer's instructions. In brief, 20 000 cells/ well were plated in triplicate wells of a 96-well plate to attach overnight. Cells were either treated with vehicle alone or with 250, 500, or 900 mmol/l of 4-TBP or MBEH for 24 h. MTT reagent (tetrazole) was added to the cells and incubated in a 371C humidified chamber for 4 h. Tetrazole is converted to formazan in the mitochondria of living cells. The formazan crystals formed were solubilized in buffer (PBS) and the wavelength was read in a reader at 562 nm (BMG Labtech, Inc., Durham, North Carolina, USA). Cell viability was calculated as a percentage of absorbance of the samples relative to vehicle-treated control.
Evaluating dendritic cell maturation
Bone marrow-derived monocytes were prepared by culturing murine bone marrow cells using protocols modified by Boudreau et al. [20] . In brief, bone marrow cells were flushed aseptically from the femurs and the tibia of mice. Monocytes were enriched using the EasySep Mouse Monocyte Enrichment Kit (Vancouver, British Columbia, Canada) according to the manufacturer's instructions. To generate dendritic cell, the monocytes were grown in Roswell Park Memorial Institute medium (RPMI) (Mediatech) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 ng/ml murine granulocyte macrophage colony stimulating factor (GM-CSF) (Peprotech, Rocky Hill, New Jersey, USA), and 12.5 ng/ml murine interleukin-4 (IL-4) (Peprotech). Cells were plated at 2 Â 10 6 cells per 5 ml of media in Teflon containers (Savillex, Minnetonka, Minnesota, USA) to prevent adherence. Half of the media was replaced every other day for 7 days. On day 7, 125 mmol/l of 4-TBP, 63 or 125 mmol/l of MBEH, or 1 mg/ml lipopolysaccharide (Sigma) was added to the cells. After 24 h, cells were gently spun and stained with Hamster antimouse CD11c, CD80, CD83, CD86, and MHCII labeled with V450, allophycocyanin, phycoerythrin, phycoerythrin-cyan and fluorescein isothiocyanate fluorochromes, respectively (BD Biosciences, Sparks Maryland, USA). Initial gating was performed on live non-debris singlets, with subsequent gating toward CD11c + cells using FACS LSR-II equipment (BD Biosciences).
Real time PCR
Cytokine profiling was performed in treated mouse skin in the remaining subcutaneous tumor tissue. Sample sizes were five per group for skin samples and three for remaining tumor tissue obtained from vehicle and 1.5 mol/l MBEH-treated animals. RNA was isolated from tissue sections using TRIzol reagent (Invitrogen) and further purified using an RNeasy mini kit (Qiagen, Valencia, California, USA). Two micrograms of RNA was reverse-transcribed with superscript III (Invitrogen) and 10% of resultant cDNA was included in the real time PCR reaction. Real time PCR was performed using QuantiTect SYBR Green Master Mix (Qiagen) and samples were run in triplicate and amplified at 951C for 10 min, 951C for 15 s, 551C for 30 s, 721C for 30 s, for 50 cycles. Standard mouse primer sets and probes for interferon g (IFNg), IL-2, IL12b, IL17a, tumor necrosis factor a (TNFa), IL-10, IL-4, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Qiagen. Relative fold change in gene expression was calculated using the DDCt method after normalizing with vehicle treatment. Experiments were repeated three times with skin samples and twice with tumor samples. Representative data from a single experiment are shown.
Tumor challenge
The k14-SCF mice were treated with 1.5 mol/l MBEH or vehicle for 3 weeks after removing the pelage by application of Nair (Church and Dwight Co.). A 100 ml volume of 5 Â 10 5 B16F10 melanoma cells in PBS (Mediatech) was injected subcutaneously into the right flank of MBEH-treated and control mice. Tumor volume was recorded daily from day 10 onwards using calipers. Data were pooled from two independent experiments for a total of eight vehicle-treated and 10 MBEH-treated animals. Statistical significance of differences among treatment groups was evaluated using Student's t-test.
Results
Eliciting immune responses by 4-TBP and MBEH in human skin explants Langerhans cell abundance and migration were monitored as a measure of the elicitation phase of an immune response in human explant cultures treated with 250 mmol/l of 4-TBP or MBEH for 3 days (Fig. 1) . Representative staining for each treatment is shown in Fig. 1a . Although the total number of Langerin + cells in the epidermis remained constant (data not shown), agents 4-TBP and MBEH induced a 2.4-fold and a 2.9-fold increase in migration of Langerhans cells, respectively, towards the basal layer of the epidermis in comparison with vehicle treatment alone (P < 0.05) (Fig. 1b) . In addition, MBEH, and not 4-TBP, treatment caused a 2.0-fold increased migration into the dermis over control treatment (P < 0.01) (Fig. 1c) . These data support immune activation particularly upon MBEH treatment.
Effect of phenolic agents on dendritic cell maturation
Immature myeloid dendritic cells derived from bone marrow precursors were treated with 63 or 125 mmol/l of MBEH and 125 mmol/l of 4-TBP for 24 h. Cells stained for activation markers were quantified in live CD11c positive cells (Fig. 2) . Although no activation was observed upon 4-TBP treatment, 1.6-fold, 1.3-fold, 1.1-fold, and 1.1-fold activations for CD80, CD83, CD86, and MHCII, respectively, was observed upon MBEH treatment. Such limited activation and maturation may contribute to the migratory behavior of dendritic cell subsets in response to MBEH, but not 4TBP treatment.
Differential response on topical application of bleaching agents in mice C57BL/6 mice were shaved biweekly to remove the ventral pelage and topically treated with 100 ml of 1.5 mol/l MBEH or 4-TBP on alternating days for 6 weeks. Two weeks after the cessation of treatment, mice were scanned on a flat bed scanner and changes in pigmentation of the pelage in the treatment area were measured by image analysis. MBEH treatment induced a 20.5% reduction in pigmentation (P < 0.0001), while 4-TBP treatment induced 2.8% depigmentation (P < 0.01) relative to vehicle treatment (Fig. 3b) . Scanned mice images were shown in Fig. 3a . These data show that MBEH penetrates the mouse skin at least to the follicular level.
Modeling epidermal pigmentation more similar to the human skin Shaven ventral skin of k14-SCF mice was topically treated with 1 mol/l concentration of 4-TBP or MBEH on alternating days for 14 weeks. Changes in the pigmentation levels upon treatment with vehicle, 4-TBP, or MBEH were shown in the scanned images of k14-SCF mice skin, as well as among the regrown pelage in Figs 4a and c. The percentage change in pigmentation was quantified relative to vehicle treatment. 4-TBP treatment increased epidermal pigmentation by 8.5% (P < 0.01) possibly representing postinflammatory hyperpigmentation of the skin, though no significant change in pigmentation level was observed for regrown hair (Fig. 4b) . MBEH, however, caused 6.5% depigmentation (P < 0.05) in epidermal skin, and 12.9% (P < 0.0001) in hair when compared with vehicle treatment (Fig. 4d) . This dataset shows that MBEH has a depigmenting effect on both skin and hair follicles in mice.
Immune cell influx in response to MBEH versus 4-TBP exposure observed in vivo T cell and macrophage influx to the skin was quantified by staining for CD3 + and CD68 + cells in epidermal and dermal skin regions, respectively, treated with 1 mol/l concentration of either bleaching agents in k14-SCF mice for 14 weeks. MBEH treatment induced a 2.0-fold increase in T cell infiltration (P < 0.05), whereas 4-TBP . Mean and standard error were calculated and statistical significance was evaluated by Students' t-test (n = 3) for epidermal measurements and (n = 4) for dermal measurements. *P < 0.05; **P < 0.01.
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treatment resulted in an 0.5-fold reduction in the T cell number when compared with control-treated skin (not significant) as shown in Fig. 5a . A similar trend was observed upon macrophage infiltration to the dermal area of treated k14-SCF skin. MBEH treatment induced a 2.4-fold increase in CD68 + cells (P < 0.01), while 4-TBP treatment did not result in a significant increase in macrophage infiltration compared with vehicle-treated skin (Fig. 5b) . This further supports the concept that MBEH activates an immune response, while no difference was observed upon 4-TBP treatment.
Cytokine profiling in monobenzyl ether of hydroquinone-treated mouse skin Cytokine environment was studied in frozen C57BL/6 mice skin after treatment with vehicle or 1.5 mol/l MEBH for 6 weeks (Fig. 6) . Increases in the relative transcript levels of TNF-a, IFN-g, and IL-2 were observed at a 2.8-fold, 2.4-fold, and 2.2-fold, respectively, over vehicle treatment. Expression levels of IL-10, IL-4, IL-12, and IL-17 were not altered, thus supporting a Th1-mediated immune response.
Cytotoxicity of bleaching agents toward B-16 melanoma cells and mouse melanocytes
The viability of cultured B16 melanoma cells and melanocytes (derived from k14-SCF mice) in response to 250, 500, and 900 mmol/l concentrations of 4-TBP or MBEH for 24 h was determined by MTT assays. In Fig. 7 , data are shown from two independent experiments. Vehicletreatment served as a control for all cell types. The viability of mouse melanocytes was reduced by 23, 40, and 62% upon 250, 500, and 900 mmol/l 4-TBP treatments, respectively, while no significant change in viability was observed in B16F10 melanoma cells (Fig. 7a) . Similarly, a 30, 48, and 59% reduction in mouse melanocytes was observed upon 250, 500, and 900 mmol/l of MBEH treatment, respectively. However, no significant difference was observed in the viability of B16F10 melanoma cells even at the highest concentration of MBEH (Fig. 7b) . This confirms that mouse melanocytes were sensitive to bleaching agents 4-TBP and MBEH as shown earlier for human melanocytes, however, melanoma cells are highly resistant to the same chemicals. Mean and standard error were calculated and statistical significance was evaluated by Student's t-test (n = 5). **P < 0.01; ***P < 0.0001. Tumor challenge of k14-SCF mice with B-16 melanoma cells A 1.5 mol/l MBEH cream or vehicle alone was applied to the skin of k14-SCF mice for 3 weeks before a subcutaneous challenge with 500 000 B16F10 melanoma cells. Treatment was stopped a week before challenging the mice with tumor. The tumor volume was measured daily from day 10 onwards. Data from two independent experiments were combined as shown in Fig. 8 . A significant difference in tumor growth between the vehicle group and the MBEH-treated group was observed at days 11, 12, 13, and 14 postchallenge. On day 14, an average tumor volume of 401 mm 3 was measured for vehicle-treated mice, whereas MBEH-treated mice displayed an average tumor volume of 91 mm 3 (P < 0.05). Mice were euthanized on day 14.
Cytokine profiling in the tumor environment
Expression levels of proinflammatory and anti-inflammatory cytokines were quantified using quantitative reverse transcription-PCR in the remaining tumor tissue after challenging MBEH-pretreated k14-SCF mice with B16 melanoma cells (Fig. 9 ). In parallel with the cytokine environment observed in C57BL/6 mice skin after treatment with MBEH, increased expression levels of TNFa, IFN-g, IL-2, and IL-12 were observed with a relative increase of 5.1-fold, 3.7-fold, 3.4-fold, and 7.1-fold over vehicle treatment. Interestingly, in addition to a Th1 environment, substantial levels of IL-17 were also observed with a 7.6-fold increase over vehicle treatment. Expression levels of IL-4 and IL-10 were also observed to increase by 2.8-fold and 1.9-fold, respectively, over vehicle treatment; overall, these data confirm a Th1-mediated immune response correlating with increased antitumor reactivity.
Infiltration of cytotoxic T cells in the tumor tissue
The consequence of a Th1 cytokine environment was further established in the remaining tumor tissue, by quantifying the abundance of cytotoxic CD8 + T cells. Representative stainings are shown for three mice/group (Fig. 10) . CD8 + T-cell infiltration was 4.7-fold increased in remaining tumor tissue from three animals compared with tumors resected from three vehicle-treated animals, which was significant at a P value of less than 0.01 in Student's t-test. These data strongly suggest that antitumor protection provided by MBEH pretreatment is mediated by cytotoxic T cells.
Discussion
Vitiligo patients with advanced disease can opt for depigmentation therapy, wherein topical application of bleaching agents is used to remove any remaining pigmentation [1] . Here, we analyze the mechanism of depigmentation within a tissue context, thus exploring the exciting concept that such bleaching agents may be used in the chemoprevention of malignant melanoma.
The data presented here show that depigmentation in response to MBEH can be reproduced in an in-vivo mouse model. In accordance with our earlier studies, the increased sensitivity of melanocytes to MBEH as compared with 4-TBP in vitro [5] is accompanied by actual greater treatment efficacy in vivo. Contrary to expectation, depigmentation of the pelage occurred more readily than depigmentation of the skin. This may, in part, be a consequence of the densely populated and heavily melanized epidermis of k14-SCF mice, as we have previously reported that melanin may act as a protective agent against the cytotoxic effects of MBEH [5] .
Such data are of particular importance as the elimination of melanocytes from the skin and hair follicles can theoretically serve as an alternative to 'elective surgery' offered for patients with mutations in tumor-associated genes [21, 22] . For example, such elective surgery is offered to patients with mutations in BRCA-1 or BRCA-2 where the odds of developing breast or ovarian cancer can increase from approximately 1% to virtually 100% [22] . As preventive surgery is out of the question for familial melanoma patients, the concept of chemoprevention proposed here can offer a much-needed alternative for patients with mutations in Ink4A/Arf or CDK4 genes [23, 24] .
As we have mentioned earlier, sensitivity to MBEH is specific for melanocytes in the epidermis but other cell types can also display similar sensitivity to both MBEH and 4-TBP, including fibroblasts [5] . This precludes the ). Mean and standard error were calculated and statistical significance was evaluated by Student's onetailed t-test. *P < 0.05; **P < 0.01. use of bleaching phenols in systemic applications, which is desirable in a therapeutic setting for melanoma. Indeed, several investigators have suggested the use of bleaching agents in the treatment of melanoma [25] .
It is an intriguing concept that bleaching agents can serve as a prodrug to be selectively converted by enzymes uniquely expressed by melanocytes and melanoma cells to generate toxic quinones. In fact, it has been proposed that resulting quinones may, in turn, convert molecules in close proximity into increasingly immunogenic moieties according to the 'haptenization theory' [6, 7] . In this regard, the accelerated depigmentation in response to MBEH in the order of magnitude observed here further suggests that part of the depigmentation effects observed in vivo may actually be indirect. Statistical significance of differences among treatment groups was evaluated using Student's t-test *P < 0.05. Prophylactic MBEH treatment in vivo Hariharan et al. 123 We postulate that the necrotic pathway of cell death induced by MBEH, as opposed to apoptosis after exposure to 4-TBP, may differentially affect processing and presentation of melanocyte antigens, and selectively lead to an immune response after MBEH exposure [5, 26, 27] . Indeed, the data presented here strongly support elicitation of an immune response in response to MBEH, which is not found after 4-TBP application. First, we observed Langerhans cell emigration from the epidermis of human skin in response to MBEH, whereas after 4-TBP application these cells were merely found in basal position, thus remaining within the epidermis. It is unlikely that antigens processed by intraepidermal Langerhans cells will be presented to T cells in draining lymph nodes, thus preventing an influx of T cells to the skin. Such investigations required moving from the 'ex vivo' model in human tissue to 'in vivo' studies by engaging C57BL/6 or k14-SCF mice with epidermal melanocytes. In these in-vivo (cursive) studies, it was observed that both macrophages and T cells primarily driven by Th1 cytokines infiltrate the skin in response to MBEH, but not 4-TBP. A combination of infiltrating macrophages and T cells is similarly observed in vitiligo and other autoimmune disease and this combined effect might be responsible for the removal of target cells under stress [28] [29] [30] .
To assess whether the inflammatory conditions encountered in MBEH-treated skin were accompanied by reactivity to cells of the melanocyte lineage, as well as to test for actual antitumor protection of the treatment at hand, mice depigmenting in response to MBEH was then challenged with B16 melanoma cells subcutaneously introduced in depigmented areas. It should be noted that MBEH treatments were ceased well before tumor challenge, rendering the circumstances unlikely for a direct (biochemical) effect on B16 melanoma cells. Such biochemical responses to bleaching agents were further investigated in vitro, and it became apparent that similar to human melanoma cells (unpublished data), B16 cells are highly insensitive to direct exposure to bleaching phenols. It is possible that reduced sensitivity of MBEH toward melanoma cells can be explained by toxin pumps activated in response to malignant transformation that likewise render tumor cells increasingly insensitive to antiproliferative agents [31, 32] .
Finally, elevated levels of Th1/Th17 cytokines along with a marked infiltration of CD8 + T cells strongly suggest that significant inhibition of tumor growth upon MBEH pretreatment was primarily due to cytotoxic T cell activity.
It has been reported that elimination of melanocytes by MBEH is permanent [1] . Therefore, it can be expected that memory responses are established by depigmentation treatment. For melanocytes that are not eliminated by MBEH treatment or due to the immune response that follows, it may be important to drive recall responses in patients where remaining melanocytes malignantly transform at a later time point. This question was addressed by van den Boorn et al. [12] , in their recent publication, where MBEH treatment was combined with adjuvants imiquimod and CpG. Antitumor reactivity was observed even 165 days after cessation of the treatment, thus supporting lasting effects.
As melanocytes are involved in photo-protection, removal of melanocytes can increase the risk of nonmelanoma skin cancer occurrence. However, as erythema rapidly develops in depigmented skin in response to ultraviolet light, treated patients tend to avoid sun exposure. Indeed, this explains the infrequent occurrence of nonmelanoma skin cancer in vitiligo patients [33, 34] .
In conclusion, our data support the fact that the greatest potential of bleaching phenols in antitumor treatment revolves around prophylactic applications. We have shown that treatment by bleaching phenols can be mimicked in mice closely reflecting human skin pigmentation by the presence of melanocytes in the epidermis. In addition, the data clearly show that the application of MBEH as a single agent should be restricted to topical use, whereas there is little to no efficacy toward melanoma tumor cells. Most excitingly, these data support the concept that topical application of bleaching phenols can serve as a prophylactic agent to support the prevention of tumor growth in familial melanoma patients and patients concerned about tumor recurrences. Such protection is offered in a two-tiered approach, by eliminating precursor cells of the melanocyte lineage that can otherwise malignantly transform, and by eliciting an immune response to melanocytes to support removal of melanocytes from sites not exposed to MBEH, as well as to melanoma cells that share expression of melanocyte differentiation antigens. In particular, gp100, melanoma antigen recognized by T cells-1, and tyrosinase are among the most immunogenic molecules expressed by melanoma cells [6, 35, 36] . Taken together, the data offer preclinical support for the establishment of topical depigmentation as adjuvant prophylactic treatment against melanoma.
